Lyell Immunopharma, Inc. (LYEL) Operating income 2019–2025
Lyell Immunopharma, Inc. (LYEL) annual operating income history from SEC filings — each fiscal year as reported.
-$269.4MFY2025 · since FY2019: -$102.1M → -$269.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$269.4M | +24.9% |
| FY2024 | -$358.8M | -45.2% |
| FY2023 | -$247.0M | -32.0% |
| FY2022 | -$187.1M | +12.9% |
| FY2021 | -$214.8M | -1.3% |
| FY2020 | -$211.9M | -107.6% |
| FY2019 | -$102.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More LYEL financial trends
LYEL RevenueLYEL Net incomeLYEL Net marginLYEL Gross profitLYEL Gross marginLYEL Operating marginLYEL Operating cash flowLYEL Free cash flowLYEL Capital expendituresLYEL Return on equityLYEL Stock buybacksLYEL Dividends paidLYEL Total assetsLYEL Total liabilitiesLYEL Shareholders’ equityLYEL overview →